Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s stock price reached a new 52-week low on Thursday . The company traded as low as GBX 4.11 ($0.05) and last traded at GBX 4.27 ($0.05), with a volume of 28485160 shares changing hands. The stock had previously closed at GBX 7.10 ($0.09).
Analyst Upgrades and Downgrades
Separately, Shore Capital reissued a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday.
Get Our Latest Research Report on POLB
Poolbeg Pharma Trading Down 1.6 %
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Recommended Stories
- Five stocks we like better than Poolbeg Pharma
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- How to Evaluate a Stock Before Buying
- Nebius Group: The Rising Star in AI Infrastructure
- What Are Trending Stocks? Trending Stocks Explained
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
